NCT04826562View on ClinicalTrials.gov

Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

September 26, 2021

Primary Completion Date

October 6, 2023

Study Completion Date

December 30, 2023

Conditions

Human Immunodeficiency Virus

Interventions

DRUG

Dolutegravir/Lamivudine

single tablet antiretroviral

Trial Locations (1)

07102

Saint Michael's Medical Center, Newark

Sponsors

Collaborators (1)

ViiV Healthcare

All Listed Sponsors

collaborator

ViiV Healthcare

INDUSTRY

lead

Saint Michael's Medical Center

OTHER